Compositions and methods for monitoring and detecting cancerous conditions
AssigneePhigenix, Inc.
InventorCarlton D. DONALD
Life of this patent
Estimating the term…
Abstract
A method for monitoring or detecting a prostate condition in a subject comprises determining Engrailed-2 (EN2) gene, Paired Box 2 (PAX2) gene, and/or β defensin-1 (DEFB1) gene expression levels in a biological sample from the subject. The expression levels of EN2, PAX2 and/or DEFB1 gene are correlated with cancerous, pre-cancerous, or non-cancerous prostate conditions.
Claims20
A method for monitoring or detecting a prostate condition in a subject, comprising:
- measuring expression levels of Engrailed-2 (EN2) gene, paired box homeotic gene 2 (PAX2) and β-defensin-1 (DEFB1) gene in a biological sample from said subject;
- and
- comparing the expression levels of EN2, PAX2 and DEFB1 genes in said sample to reference expression levels of EN2, PAX2 and DEFB1 genes,
- wherein elevated expression levels of both EN2 and PAX2 genes, coupled with a decresed expression level of DEFB1 gene, are indicative of a cancerous or pre-cancerousprostate condition.
A method for monitoring or detecting cancerous, pre-cancerous, or non-cancerous prostate conditions in a subject, comprising:
- determining a PAX2 gene expression level in cells from the prostate of said subject;
- determining an EN2 gene expression level in said cells;
- and
- comparing said PAX2 and EN2 gene expression levels to reference levels of PAX2 and EN2 gene expression;
- wherein increases of at least 2-fold over said reference levels in both PAX2 and EN2 gene expression in said cells are indicative of prostate cancer, prostate intraepithelial neoplasia (PIN) or a risk for developing prostate cancer.
A method for monitoring or detecting cancerous, pre-cancerous, or non-cancerous prostate conditions in a subject, comprising:
- determining a DEFB1 gene expression level in cells from the prostate of said subject;
- determining an EN2 gene expression level in said cells;
- and
- comparing said DEFB1 and EN2 gene expression levels to reference levels of DEFB1 and EN2 gene expression;
- wherein an increase of at least 100% over the referenc level of EN2 gene expression and a decrease of at least 50% over the referenc level of DEFB1 in said cells are indicative of prostate cancer, prostate intraepithelial neoplasia (PIN) or a risk for developing prostate cancer.
A kit for monitoring or detecting a prostate condition in a subject, comprising:
- reagents for detecting an expression level of EN2 gene;
- and
- reagents for detecting expression levels of PAX2 and/or DEFB1 genes.
Dependencies are inferred from the claim text.